Thermo Fisher Scientific CD273 (PD-L2) Monoclonal Antibody (3.2.B8), Functional Grade, In Vivo GOLD

Applications

Tested Dilution

Publications

Western Blot (WB)

Assay-dependent

-

Flow Cytometry (Flow)

Assay-dependent

-

Inhibition Assays (IA)

Assay-dependent

-

Blocking Assay (BLOCK)

Assay-dependent

-

Product Specifications

Species Reactivity

Human, Mouse

Host/Isotype

Mouse / IgG1

Class

Monoclonal

Type

Antibody

Clone

3.2.B8

Immunogen

Made in PD-L2 knockout mouse fusion partner X63-Ag8.653 myeloma cells

Conjugate

Functional Grade Functional Grade Functional Grade

Form

Liquid

Concentration

≥5.0 mg/mL

Purification

Protein A/G

Storage buffer

PBS, pH 7.2-7.4

Contains

no preservative

Storage conditions

4°C short term, -80°C long term

Shipping conditions

Ambient (domestic); Wet ice (international)

Product Specific Information

Specificity: Clone 3.2.B8 recognizes an epitope on mouse/human PD-L2 and has been shown to bind to both mouse and human PD-L2 equally well

Endotoxin Level: ≤ 1.0 EU/mg as determined by the LAL method. Purity: >95% by SDS Page; ≥95% monomer by analytical SEC.

Product Preparation: Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

Storage and Handling: Functional grade preclinical antibodies may be stored sterile as received at 2-8 C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80 C. Avoid Repeated Freeze Thaw Cycles.

This antibody has been tested in the following applications: Flow Cytometry, Blocking.

Target Information

Programmed death-ligand 2 (PD-L2), or B7-DC, is a member of the B7 ligand family within the immunoglobulin superfamily that, along with programmed death-ligand 1 (PD-L1), acts as a ligand for programmed cell death protein 1 (PD-1). Though expressed primarily in dendritic cells, PD-L2 expression can be induced on a wide variety of immune and non-immune cells depending on the microenvironment. PD-L2 expression is particularly upregulated in the presence of Th2 cytokine, IL-4, as well as Th1 cytokines, TNF-alpha and IFN-gamma to a lesser degree. While generally expressed at lower levels compared to PD-L1, PD-L2 demonstrates a 2 to 6 times higher relative affinity to PD-1 than PD-L1. PD-1 and its ligands are referred to as inhibitory immune checkpoint molecules in that they provide useful negative feedback during physiological homeostasis. Ligation of PD-L2 or PD-L1 inhibits activation, proliferation, and cytokine secretion (e.g. IFN-gamma, IL-10) in T cells, ultimately dampening immune response. Conversely, studies have shown that PD-L2 can also stimulate T cell proliferation and cytokine production, even in PD-1-deficient T cells, suggesting additional receptors. Recent studies have concluded that PD-L2 also binds to a second receptor, repulsive guidance molecule b (RGMb), which was originally identified as a receptor for bone morphogenetic proteins (BMPs). RGMb is expressed in the central nervous system, as well as in macrophages, however, its role in immunity is only beginning to emerge. Interaction between PD-L2 and RGMb regulates the development of respiratory tolerance in the lung through BMP and/or neogenin signaling pathways. The naturally occurring human PD-L2 monomer consists of a 201-amino-acid extracellular domain, a 21-amino-acid transmembrane domain, and a 32-amino-acid cytoplasmic domain.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.